Zhong Zhe, Ye Min, Yan Fuling
Department of Neurology, Affiliated Zhongda Hospital, School of Medicine, Research Institution of Neuropsychiatry, Southeast University, Nanjing, China.
Department of Neurology, Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Front Neurol. 2023 Jun 2;14:1046910. doi: 10.3389/fneur.2023.1046910. eCollection 2023.
Parkinson's disease (PD) is the second most common neurodegenerative disease globally. Levodopa (L-dopa) has been the cornerstone for treating Parkinson's since the 1960s. However, complications such as "wearing-off" and dyskinesia inevitably appear with disease progression. With the further development of microbiomics in recent years, It has been recognized that gut microbiota plays a crucial role in Parkinson's disease pathogenesis. However, Little is known about the impact of gut microbiota in PD treatment, especially in levodopa metabolism. This review examines the possible mechanisms of gut microbiota, such as , , and affecting L-dopa absorption. Furthermore, we review the current status of gut microbiota intervention strategies, providing new insights into the treatment of PD.
帕金森病（PD）是全球第二常见的神经退行性疾病。自20世纪60年代以来，左旋多巴（L-多巴）一直是治疗帕金森病的基石。然而，随着疾病进展，诸如“剂末现象”和异动症等并发症不可避免地出现。近年来，随着微生物组学的进一步发展，人们已经认识到肠道微生物群在帕金森病发病机制中起着至关重要的作用。然而，关于肠道微生物群在帕金森病治疗中的影响，尤其是在左旋多巴代谢方面，人们知之甚少。本综述探讨了肠道微生物群影响L-多巴吸收的可能机制，如 、 和 。此外，我们综述了肠道微生物群干预策略的现状，为帕金森病的治疗提供了新的见解。
